title: Reversible translocation of phosphoinositide 3-kinase to the cytoskeleton of ADP-aggregated human platelets occurs independently of Rho A and without synthesis of phosphatidylinositol (3,4)-bisphosphate.
abstract: The aim of our study was to evaluate the effect of ADP and the role of cytoskeleton reorganization during reversible and irreversible platelet aggregation induced by ADP and thrombin, respectively, on the heterodimeric (p85alpha-p110) phosphoinositide 3-kinase translocation to the cytoskeleton and its activation. Reversible ADP-induced aggregation was accompanied by a reversible reorganization of the cytoskeleton and an increase in levels of the regulatory subunit p85alpha in this cytoskeleton similar to the increase observed in thrombin-activated platelets. This translocation followed a course parallel to the amplitude of aggregation. No increase in levels of both phosphatidylinositol (3, 4)-bisphosphate (PtdIns(3,4)P2) and phosphatidylinositol-(3,4,5)P3 could, however, be detected even at the maximum aggregation and PI 3-kinase alpha translocation. Moreover, in contrast to the situation for thrombin stimulation, the GTP-binding protein RhoA was hardly translocated to the cytoskeleton when platelets were stimulated with ADP, whereas translocation of pp60(c-)src and focal adhesion kinase did occur. These results suggest (i) translocation of signaling enzymes does not necessarily imply their activation, (ii) the reversibility of ADP-induced platelet aggregation may be the cause or the result of a lack of PI 3-kinase activation and hence of PtdIns(3,4)P2 production, and (iii) RhoA does not seem to be involved in the ADP activation pathway of platelets. Whether PtdIns(3,4)P2 or RhoA may contribute to the stabilization of platelet aggregates remains to be established.
authors.affiliation: INSERM U.311, ETS, 10 rue Spielmann, 67065 Strasbourg, Hôpital Purpan, 31059 Toulouse, France. christian.gachet@etss.u-strasbg.fr
authors.forename: C
authors.initials: C
authors.lastname: Gachet
authors.forename: B
authors.initials: B
authors.lastname: Payrastre
authors.forename: C
authors.initials: C
authors.lastname: Guinebault
authors.forename: C
authors.initials: C
authors.lastname: Trumel
authors.forename: P
authors.initials: P
authors.lastname: Ohlmann
authors.forename: G
authors.initials: G
authors.lastname: Mauco
authors.forename: J P
authors.initials: JP
authors.lastname: Cazenave
authors.forename: M
authors.initials: M
authors.lastname: Plantavid
authors.forename: H
authors.initials: H
authors.lastname: Chap
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology*; D001692:Biological Transport; D001792:Blood Platelets / Q000502:physiology*; D003599:Cytoskeleton / Q000502:physiology*; D019204:GTP-Binding Proteins / Q000502:physiology; D006801:Humans; D019869:Phosphatidylinositol 3-Kinases; D018129:Phosphatidylinositol Phosphates / Q000502:physiology; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects*; D020742:rhoA GTP-Binding Protein
chemical_list: D018129:Phosphatidylinositol Phosphates; C060980:phosphatidylinositol 3,4-diphosphate; D000244:Adenosine Diphosphate; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor); D019204:GTP-Binding Proteins; D020742:rhoA GTP-Binding Protein